Stocks Vivus Inc

More

  • Vivus is getting the JPMorgan Healthcare Conference off to a sexy start. The company announced this morning that its late-stage experimental erectile dysfunction drug apparently gets the job done in 15 minutes.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks struggled Thursday as the dollar rose and investors remained skittish ahead of Friday's jobs report. GE, Bank of America and Ford were among the day's gainers. Alcoa skidded.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks skidded Thursday as the dollar rose, putting pressure on stocks that outweighed encouraging reports on employment and retail sales.  Bank of America, Sears and Bed, Bath &  Beyond were among the early leaders, while Alcoa stumbled.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks opened lower on Wall Street as a rising dollar pressures commodity prices and outweighed another round of positive news in the job market.

  • Winterizing Your Portfolio - A CNBC Special Report

    Another round of better-than-expected employment figures did little to assuage investors as stock futures pointed to a negative open for Wall Street.

  • pills_prescription_200.jpg

    I can’t wait until this drug rises to the level where it gets on Joe Kernen’s radar screen because, boy, is he gonna have a good time (not just with the drug perhaps, but mostly with talking on TV about it.) A little TMI, I know, but that’s Joe.

  • The latest erectile dysfunction drug is showing promise of working even faster than those already on the market. Considering it's $3.5 billion market, what's the trade?

  • VVUS this morning unveiled positive late-stage test results on the ED pill. The company touts that it takes effect in less than 30 minutes and it's out of your system within six hours or so.

  • The Lightning Round is extended in this CNBC.com exclusive feature.

  • obesity_man_200.jpg

    I end the week as I started it: blogging about Vivus and the three-contestant race to make a new prescription diet pill.

  • MM_promo_Cramerica_Challenge_530x50.jpg

    Cramer makes the call on viewers' favorite stocks.

  • Patients on Vivus' late-stage developmental diet drug, Qnexa, lost an average 37 pounds in 13 months.

  • MM_promo_Cramerica_Challenge_530x50.jpg

    Cramer makes the call on viewers' favorite stocks.

  • MM_promo_Cramerica_Challenge_530x50.jpg

    Plus, a call on two speculative drug companies.

  • MM_promo_Cramerica_Challenge_530x50.jpg

    The Lightning Round is extended in this CNBC.com exclusive feature.

  • There! I resisted writing a blog headline that attempts some tired play on words with the Arena Pharmaceuticals' clinical trial acronyms BLOSSOM and BLOOM.

  • Qnexa

    Some analysts had been telling clients recently that they thought Vivus' diet drug Qnexa could take the lead in the three-contestant race to get the next prescription diet pill on the market. But they didn't think it would take such a commanding lead.

  • Stocks closed higher after faltering for awhile on a Federal Reserve report that the economy will remain weak due largely to unemployment.

  • Futures indicated a lower open for Wall Street on Wednesday as investors paused ahead of key U.S. data, having pushed markets to 11-month highs the previous day,

  • Futures indicated a lower open for Wall Street on Wednesday as investors paused ahead of key U.S. data, having pushed markets to 11-month highs the previous day,